U.S. patent application number 13/715242 was filed with the patent office on 2013-08-22 for non-flushing niacin analogues, and methods of use thereof.
This patent application is currently assigned to Trustees of Tufts College. The applicant listed for this patent is Trustees of Tufts College. Invention is credited to William W. Bachovchin, Hung-sen Lai.
Application Number | 20130217714 13/715242 |
Document ID | / |
Family ID | 38997834 |
Filed Date | 2013-08-22 |
United States Patent
Application |
20130217714 |
Kind Code |
A1 |
Bachovchin; William W. ; et
al. |
August 22, 2013 |
Non-Flushing Niacin Analogues, and Methods of Use Thereof
Abstract
One aspect of the present invention relates to substituted
pyridines and pharmaceutically acceptable salts thereof that are
active against a range of mammalian maladies. Another aspect of the
invention relates to a pharmaceutical composition, comprising a
compound of the present invention or a pharmaceutically acceptable
salt thereof; and a pharmaceutically acceptable excipient. The
present invention also relates to methods of treating a range of
mammalian maladies or conditions, including but not limited to
hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary
artery disease, congestive heart failure, cardiovascular disease,
hypertension, coronary heart disease, angina, pellagra, Hartnup's
syndrome, carcinoid syndrome, arterial occlusive disease, obesity,
hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid
arthritis, diabetes, Alzheimer's disease, lipodystrophy, or
dyslipidemia, raising serum high-density lipoprotein (HDL) levels,
and lowering serum low-density lipoprotein (LDL) levels.
Inventors: |
Bachovchin; William W.;
(Cambridge, MA) ; Lai; Hung-sen; (Andover,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Trustees of Tufts College; |
|
|
US |
|
|
Assignee: |
Trustees of Tufts College
Boston
MA
|
Family ID: |
38997834 |
Appl. No.: |
13/715242 |
Filed: |
December 14, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12376238 |
Sep 3, 2009 |
8377971 |
|
|
PCT/US07/74960 |
Aug 1, 2007 |
|
|
|
13715242 |
|
|
|
|
60835194 |
Aug 3, 2006 |
|
|
|
Current U.S.
Class: |
514/275 ;
514/311; 514/343 |
Current CPC
Class: |
C07D 213/55 20130101;
C07D 213/80 20130101; A61P 25/28 20180101; A61P 3/10 20180101; A61P
3/04 20180101; A61P 43/00 20180101; A61P 9/10 20180101; A61K 45/06
20130101; A61P 3/06 20180101; A61P 9/08 20180101; A61P 9/12
20180101; A61K 31/4439 20130101; A61P 29/00 20180101; A61P 19/02
20180101; A61P 5/14 20180101; C07D 401/06 20130101; A61P 9/04
20180101 |
Class at
Publication: |
514/275 ;
514/343; 514/311 |
International
Class: |
A61K 31/4439 20060101
A61K031/4439; A61K 45/06 20060101 A61K045/06; C07D 213/55 20060101
C07D213/55 |
Claims
1-84. (canceled)
85. A method of treating hyperlipidemia, hypercholesterolemia,
atherosclerosis, coronary artery disease, congestive heart failure,
cardiovascular disease, hypertension, coronary heart disease,
angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial
occlusive disease, obesity, hypothyroidism, vasoconstriction,
osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's
disease, lipodystrophy, or dyslipidemia, comprising the step of:
administering to a mammal in need thereof a therapeutically
effective amount of a compound represented by structure A, or a
pharmaceutically acceptable salt thereof: ##STR00034## wherein R
represents independently for each occurrence H, alkyl, alkenyl,
alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, fluoride,
chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl; R' represents
independently for each occurrence H, alkyl, alkenyl, alkynyl, aryl,
heteroaryl, aralkyl, heteroaralkyl, alkylsulfonyl, arylsulfonyl,
heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl,
alkenylsulfonyl, alkynylsulfonyl, hydroxyl, alkoxyl, aryloxyl,
heteroaryloxyl, aralkyloxy, heteroaralkyloxy, alkenyloxy,
alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--; R'' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; and n is 1, 2, 3, or 4.
86. The method of claim 85, wherein R represents independently for
each occurrence H, fluoride, chloride, cyano, methyl, or ethyl.
87. The method of claim 85, wherein R represents independently for
each occurrence H.
88. The method of claim 85, wherein R' represents independently for
each occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl,
aralkyl, or heteroaralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
89. The method of claim 85, wherein the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
90. The method of claim 85, wherein the two instances of R' taken
together represent --(CH.sub.2).sub.4--.
91. The method of claim 85, wherein R'' represents H, alkyl, aryl,
or aralkyl.
92. The method of claim 85, wherein R'' represents H.
93. The method of claim 85, wherein n is 2.
94. The method of claim 85, wherein R represents independently for
each occurrence H; and n is 2.
95. The method of claim 85, wherein R represents independently for
each occurrence H; and the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
96. The method of claim 85, wherein R represents independently for
each occurrence H; and R'' represents H or alkyl.
97. The method of claim 85, wherein the two instances of R' taken
together represent --(CH.sub.2).sub.4--; and n is 2.
98. The method of claim 85, wherein R represents independently for
each occurrence H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and n is 2.
99. The method of claim 85, wherein R represents independently for
each occurrence H; R'' represents H or alkyl; and n is 2.
100. The method of claim 85, wherein R represents independently for
each occurrence H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and R'' represents H or alkyl.
101. The method of claim 85, wherein R represents independently for
each occurrence H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; and n is 2.
102. The method of claim 85, wherein R represents independently for
each occurrence H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; and n is 2.
103. The method of claim 85, wherein the compound is selected from
the group consisting of: ##STR00035## ##STR00036##
104. The method of claim 85, wherein the mammal is a human.
105. The method of claim 104, further comprising the step of:
co-administering to a mammal in need thereof a therapeutically
effective amount of a statin selected from the group consisting of
atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin,
pitavastatin, pravastatin, rosuvastatin, and simvastatin.
106. The method of claim 104, wherein said method treats
hyperlipidemia, hypercholesterolemia, atherosclerosis, or
dyslipidemia.
107. A method of raising serum high-density lipoprotein (HDL)
levels, comprising the step of: administering to a mammal in need
thereof a therapeutically effective amount of a compound
represented by structure A, or a pharmaceutically acceptable salt
thereof: ##STR00037## wherein R represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, fluoride, chloride, bromide, iodide, nitro, cyano,
sulfonic acid, alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl,
aralkylsulfoxyl, heteroaralkylsulfoxyl, alkenylsulfoxyl,
alkynylsulfoxyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,
aralkylsulfonyl, heteroaralkylsulfonyl, alkenylsulfonyl,
alkynylsulfonyl, hydroxyl, alkoxyl, aryloxyl, heteroaryloxyl,
aralkyloxy, heteroaralkyloxy, alkenyloxy, alkynyloxy, thiol,
alkylthio, arylthio, aralkylthio, heteroaralkylthio, alkenylthio,
alkynylthio, formyl, acyl, formyloxy, acyloxy, formylthio,
acylthio, amino, alkylamino, arylamino, heteroarylamino,
aralkylamino, heteroaralkylamino, alkenylamino, alkynylamino,
formylamino, acylamino, carboxylate, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, carboxamido, alkylaminocarbonyl,
arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl,
or heteroaralkylaminocarbonyl; R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,
aralkylsulfonyl, heteroaralkylsulfonyl, alkenylsulfonyl,
alkynylsulfonyl, hydroxyl, alkoxyl, aryloxyl, heteroaryloxyl,
aralkyloxy, heteroaralkyloxy, alkenyloxy, alkynyloxy, formyl, acyl,
amino, alkylamino, arylamino, heteroarylamino, aralkylamino,
heteroaralkylamino, alkenylamino, alkynylamino, formylamino,
acylamino, alkyloxycarbonyl, aryloxycarbonyl,
heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--; R'' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; and n is 1, 2, 3, or 4.
108. A method of lowering serum low-density lipoprotein (LDL)
levels or lowering serum lipoprotein (a) (Lp(a)) levels, comprising
the step of: administering to a mammal in need thereof a
therapeutically effective amount of a compound represented by
structure A, or a pharmaceutically acceptable salt thereof:
##STR00038## wherein R represents independently for each occurrence
H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, fluoride, chloride, bromide, iodide, nitro, cyano,
sulfonic acid, alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl,
aralkylsulfoxyl, heteroaralkylsulfoxyl, alkenylsulfoxyl,
alkynylsulfoxyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,
aralkylsulfonyl, heteroaralkylsulfonyl, alkenylsulfonyl,
alkynylsulfonyl, hydroxyl, alkoxyl, aryloxyl, heteroaryloxyl,
aralkyloxy, heteroaralkyloxy, alkenyloxy, alkynyloxy, thiol,
alkylthio, arylthio, aralkylthio, heteroaralkylthio, alkenylthio,
alkynylthio, formyl, acyl, formyloxy, acyloxy, formylthio,
acylthio, amino, alkylamino, arylamino, heteroarylamino,
aralkylamino, heteroaralkylamino, alkenylamino, alkynylamino,
formylamino, acylamino, carboxylate, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, carboxamido, alkylaminocarbonyl,
arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl,
or heteroaralkylaminocarbonyl; R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,
aralkylsulfonyl, heteroaralkylsulfonyl, alkenylsulfonyl,
alkynylsulfonyl, hydroxyl, alkoxyl, aryloxyl, heteroaryloxyl,
aralkyloxy, heteroaralkyloxy, alkenyloxy, alkynyloxy, formyl, acyl,
amino, alkylamino, arylamino, heteroarylamino, aralkylamino,
heteroaralkylamino, alkenylamino, alkynylamino, formylamino,
acylamino, alkyloxycarbonyl, aryloxycarbonyl,
heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--; R'' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; and n is 1, 2, 3, or 4.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S.
Provisional Patent Application Ser. No. 60/835,194, filed Aug. 3,
2006.
BACKGROUND OF THE INVENTION
[0002] Hyperlipidemia and hypercholesterolemia are conditions that
have a well established correlation with increased risk of other
conditions, such as heart attacks, atherosclerosis, and other
deleterious ailments. There are numerous agents available for
lowering cholesterol and lipid levels, including gemfibrizol,
probucol, and, more recently, the "statins" e.g, lovastatin.
[0003] Niacin (nicotinic acid and/or nicotinamide), a water soluble
B-complex vitamin, is used orally for the treatment of
hyperlipidemia. Niacin has been shown to be effective in reducing
total plasma cholesterol (C), low density lipoproteins LDL-C and
very low density lipoprotein triglycerides (VLDL-triglycerides),
all of which are associated with health risks. Simultaneously,
niacin raises serum levels of high density lipoproteins (HDL-C),
which are considered a "healthy" lipoprotein, in patients with
types II, III, IV, and V hyperlipoproteinemia.
[0004] Although the mechanism by which niacin alters lipid profiles
has not been well defined, its mechanisms of action have been shown
to include inhibition of free fatty acid release from adipose
tissue (see Carlson, L. A., Froberg, S. O. and Nye, E. R.,
Nicotinic acid in the rat. 11. Acute effects of nicotinic acid on
plasma, liver, heart, and muscle lipids, Acta Med Scand 180:
571-579, 1966), and increased lipoprotein lipase activity (see
Priego, J. G., Pina, M., Armijo, M., Sunkel, C. and Maroto, M. L.,
Action of etofibrate, clofibrate and nicotinic acid on the
metabolism of lipids in normolipemic rats. Short term effects and
method of action, Arch Farmacol Toxicol 5: 29-42, 1979). More than
30 million Americans have elevated blood LDL-C levels. HMG-CoA
reductase inhibitors (statins) are the most widely used class of
drugs for treating patients with elevated levels of LDL-C. Niacin,
however, is the only drug recommended by the American Heart
Association for HDL improvement in primary prevention of
cardiovascular diseases in addition to lowering LDL-C. Niacin
therapy is not only cost-effective as a monotherapy, but it is also
beneficial as a combination therapy because it complements the
effects of other classes of lipid-lowering drugs. However, niacin
is a second or third choice for isolated, hypercholesterolemia
because of a high incidence of side effects associated with oral
niacin therapy. Nevertheless, it has a therapeutic advantage as a
monotherapy when reduction of both LDL-C and triglycerides are
desired, such as for patients with severe combined
hyperlipidemia.
[0005] Niacin may also be used in combination with other
cholesterol-lowering agents, such as the "statins", to maximize
lipid-lowering activity. One study showed that a niacin/lovastatin
combination is highly effective in lowering LDL-C, triglycerides
and lipoprotein a[Lp(a)] while retaining niacin's potency in
raising HDL-C (Kashyap, M. L., Evans R., Simmons, P. D., Kohler, R.
M. and McGoven, M. E., New combination niacin/statin formulation
shows pronounced effects on major lipoproteins and well tolerated,
J Am Coll Card Suppl. A 35: 326, 2000).
[0006] Niacin has been widely used for reducing serum cholesterol
levels because it is considered a cost-effective therapy. Daily
oral doses of 2-3 g niacin in humans reduce levels of total-C and
LDL-C by an average of 20% to 30%, reduce triglyceride levels 35%
to 55%, increase HDL-C 20% to 35%, and reduce Lp(a). Niacin also
reduces total mortality as well as mortality from coronary artery
disease (see The Coronary Drug Project Research Group, JAMA 231:
360-381, 1975; and Canner, P. L., Berge, K. G., Wenger, N. K.,
Stamler, J., Friedman, L., Prineas, R. J. and Friedewald, W.,
Fifteen year mortality in Coronary Drug Project patients: long-term
benefit with niacin, J Am Coll Cardiol 8: 1245-1255, 1986.) and it
helps to slow or reverse the progression of atherosclerosis (see
Blankenhorn, D. H., Nessim, S. A., Johnson, R. L., Samnarco, M. E.,
Azen, S. P. and Cashin-Hemphill, L., Beneficial effects of combined
colestipol-niacin therapy on coronary atheroscloerosis and coronary
venous bypass grafts, JAMA 257: 3233-3240, 1987; and
Cashin-Hemphill L.; Mack, W. J., Pogoda, J. M., Samnarco, M. E.,
Azen, S. P. and Blankenhorn, D. H., Beneficial effects of
colestipol-niacin on coronary atherosclerosis. A 4-year follow-up,
JAMA 264: 3013-3017, 1990).
[0007] Unfortunately, oral niacin therapy has side effects that
limit its utility. Although niacin is a vitamin, it must be used in
therapeutic doses to lower cholesterol. At these doses, both
immediate-release and sustained-release niacin can have several
side effects. The most common side effect of niacin is flushing, a
warm feeling in the skin usually associated with redness and
sometimes itching. Flushing is not dangerous, but most patients
find it very uncomfortable, which seriously limits patient
compliance with niacin therapy. Niacin-induced flushing can be
substantially attenuated by pretreatment with cyclooxygenase
inhibitors, suggesting that the vasodilation is caused by a
prostaglandin-mediated mechanism (see Carlson, L. A., Nicotinic
acid and inhibition of fat mobilizing lipolysis. Present status, of
effects on lipid metabolism, Adv Exp Med Biol 109: 225-23 8,
1978).
[0008] Liver function tests are always monitored in patients taking
niacin since elevation of serum transaminase levels has been
associated with niacin treatment, and sustained-release niacin
formulations have been associated with more serious liver problems
(see McKenney, J. M., Proctor, J. D., Harris, S., and Chinchili, V.
M., A comparison of the efficacy and toxic effects of sustained- vs
immediate-release niacin in hypercholesterolemic patients, JAMA
271: 672-777, 1994; and Stafford, R. S., Blumenthal, D. and
Pasternak, R. C., Variations in cholesterol management practices of
U.S. physicians, J Am Coll Cardiol 29: 139-146, 1997). Other known
side effects of oral niacin therapy include activation of peptic
ulcers, gout, and worsening of diabetes control. Accordingly, the
safety and efficacy of oral niacin therapy is undermined by the
need for careful clinical monitoring and the compound's side-effect
profile.
SUMMARY OF THE INVENTION
[0009] One aspect of the present invention relates to substituted
pyridines and pharmaceutically acceptable salts thereof that are
active against a range of mammalian maladies. In certain
embodiments, said pyridines or salts thereof comprise at the
3-position or 5-position a substituent comprising a functional
group that is substantially anionic at physiological pH. In certain
embodiments, said pyridines or salts thereof comprise at the
2-position or 6-position a substituent comprising a functional
group that is electron donating to the pyridine ring. In certain
embodiments, said pyridines or salts thereof comprise at the
5-position a substituent comprising a functional group that is
substantially anionic at physiological pH; and at the 2-position a
substituent comprising a functional group that is electron donating
to the pyridine ring.
[0010] Another aspect of the invention relates to a pharmaceutical
composition, comprising a compound of the present invention or a
pharmaceutically acceptable salt thereof; and a pharmaceutically
acceptable excipient. Yet another aspect of the invention relates
to a pharmaceutical composition, comprising a compound of the
present invention or a pharmaceutically acceptable salt thereof;
niacin; and a pharmaceutically acceptable excipient. Another aspect
of the invention relates to a pharmaceutical composition,
comprising a compound of the present invention or a
pharmaceutically acceptable salt thereof; a statin selected from
the group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol; and a pharmaceutically
acceptable excipient. The present invention also relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin; a
statin selected from the group consisting of atorvastatin,
cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin,
pravastatin, rosuvastatin, simvastatin, gemcabene, and probucol;
and a pharmaceutically acceptable excipient.
[0011] The present invention also relates to a method of treating
hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary
artery disease, congestive heart failure, cardiovascular disease,
hypertension, coronary heart disease, angina, pellagra, Hartnup's
syndrome, carcinoid syndrome, arterial occlusive disease, obesity,
hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid
arthritis, diabetes, Alzheimer's disease, lipodystrophy, or
dyslipidemia, comprising the step of administering to a mammal in
need thereof a therapeutically effective amount of a compound or
pharmaceutical composition of the present invention. Another aspect
of the present invention relates to a method of raising serum
high-density lipoprotein (HDL) levels, comprising the step of
administering to a mammal in need thereof a therapeutically
effective amount of a compound or pharmaceutical composition of the
present invention. Yet another aspect of the present invention
relates to a method of lowering serum low-density lipoprotein (LDL)
levels, comprising the step of administering to a mammal in need
thereof a therapeutically effective amount of a compound or
pharmaceutical composition of the present invention.
BRIEF DESCRIPTION OF THE FIGURES
[0012] FIG. 1 depicts various niacin analogues of the present
invention.
[0013] FIG. 2 tabulates the effects of various niacin analogues of
the present invention on PGD2 release and inhibition of HDL
uptake.
[0014] FIG. 3 depicts various niacin analogues of the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0015] The invention will now be described more fully with
reference to the accompanying examples, in which certain preferred
embodiments of the invention are shown. This invention may,
however, be embodied in many different forms and should not be
construed as limited to the embodiments set forth herein; rather,
these embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art.
Overview
[0016] One aspect of the invention relates to niacin analogues for
use in raising serum HDL levels in mammals. The compounds of the
invention have equal or greater HDL-raising ability than niacin
while having less or no propensity to induce flushing, an
undesirable side effect of niacin itself when used in doses
sufficient to raise serum HDL levels. In certain embodiments, key
structural features appear to include the placement of a negatively
charged group at a greater distance from the pyridine ring in a
sterically constrained trans configuration relative to the ring
and/or the absence of a carbonyl oxygen in the position analogous
to that occupied by the carboxyl group in niacin.
[0017] For example, 4-pyridin-3-yl-but-3-enoic acid (2035) reduces
HDL uptake by Hep-G2 cells, which is an assay that serves as proxy
for HDL-raising activity, essentially as well as niacin and yet has
very much less ability to induce PDG2 release by THP-1 macrophages,
which is an assay that serves as proxy for flush inducing activity
(FIG. 1 and Table 1) while the structurally very similar compounds,
2040, 2038, and 2230A (FIG. 1) have no HDL-raising activity, yet
are more potent that niacin itself in inducing flushing (Table 1).
The results also indicate that the HDL-raising activity niacin and
therefore of niacin analogs like 2235 can be improved by
substitutions to the niacin ring in the position para to the
carboxylate group as illustrated by 2230C (FIG. 1, and Table 1).
2030C is niacin with a substitution para to the carboxylate group.
The results in Table 1 show this molecule is better than niacin
itself in raising HDL. However it retains the ability to generate
flush. We propose that an improved niacin analog can be constructed
that has greater HDL-raising activity than niacin and greatly
reduced propensity to generate flush by adding substitutent in the
para position of 2230C to 2035.
Compounds of the Invention
[0018] In certain embodiments, the present invention relates to a
compound represented by structure A, or a pharmaceutically
acceptable salt thereof:
##STR00001##
wherein
[0019] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0020] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--; --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6;
[0021] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
and
[0022] n is 1, 2, 3, or 4.
[0023] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0024] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0025] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0026] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; or the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0027] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0028] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0029] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
[0030] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0031] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H.
[0032] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0033] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and n is 2.
[0034] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and the two instances of R' taken together represent
--(CH.sub.2).sub.4--.
[0035] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and n is 2.
[0036] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H or alkyl.
[0037] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; and n is 2.
[0038] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl; R' represents independently for each occurrence H,
alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or
heteroaralkyl; or the two instances of R' taken together represent
--(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--, --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, or --(CH.sub.2).sub.6--; and R'' represents H
or alkyl.
[0039] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and R'' represents H or alkyl.
[0040] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and R'' represents H or alkyl.
[0041] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; and n is 2.
[0042] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure A or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; and n is 2.
[0043] In certain embodiments, the present invention relates to a
compound represented by structure B, or a pharmaceutically
acceptable salt thereof:
##STR00002##
wherein
[0044] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0045] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
[0046] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
and
[0047] m is 1, 2, or 3.
[0048] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0049] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0050] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0051] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H or alkyl.
[0052] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H.
[0053] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0054] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H. In certain embodiments, the
present invention relates to any of the aforementioned compounds
represented by structure B or the pharmaceutically acceptable salts
thereof and the attendant limitations, wherein m is 1.
[0055] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R' represents independently for each occurrence H.
[0056] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H or alkyl.
[0057] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H.
[0058] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H; and R'' represents H or alkyl.
[0059] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H; and R'' represents H.
[0060] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; and m is
1.
[0061] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; and m is 1.
[0062] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H; and m is 1.
[0063] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H; R'' represents H or alkyl; and m is 1.
[0064] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H; R'' represents H; and m is 1.
[0065] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; and R''
represents H or alkyl.
[0066] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; and R''
represents H.
[0067] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; R''
represents H or alkyl; and m is 1.
[0068] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure B or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; R''
represents H; and m is 1.
[0069] In certain embodiments, the present invention relates to a
compound represented by structure C, or a pharmaceutically
acceptable salt thereof:
##STR00003##
wherein
[0070] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0071] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--;
[0072] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
[0073] R.sup.3 represents independently for each occurrence H,
alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or
heteroaralkyl;
[0074] n is 1, 2, 3, or 4; and
[0075] m is 1, 2, or 3.
[0076] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0077] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0078] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0079] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; or the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0080] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0081] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0082] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
[0083] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0084] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H.
[0085] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R.sup.3 represents independently for each
occurrence H or alkyl.
[0086] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R.sup.3 represents independently for each
occurrence H.
[0087] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0088] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein m is 1.
[0089] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R.sup.3 represents independently for each occurrence H.
[0090] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; and R.sup.3 represents independently
for each occurrence H or alkyl.
[0091] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H; and R.sup.3 represents independently for each
occurrence H.
[0092] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; and R.sup.3
represents independently for each occurrence H or alkyl.
[0093] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; and R.sup.3 represents
independently for each occurrence H.
[0094] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; R.sup.3 represents
independently for each occurrence H or alkyl; and n is 2.
[0095] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; R.sup.3 represents
independently for each occurrence H; and n is 2.
[0096] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R.sup.3 represents independently for each occurrence H; and m is
1.
[0097] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; R.sup.3 represents independently for
each occurrence H or alkyl; and m is 1.
[0098] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H; R.sup.3 represents independently for each
occurrence H; and m is 1.
[0099] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; R.sup.3 represents
independently for each occurrence H or alkyl; and m is 1.
[0100] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; R.sup.3 represents
independently for each occurrence H; and m is 1.
[0101] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; R.sup.3 represents
independently for each occurrence H or alkyl; n is 2; and m is
1.
[0102] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure C or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; R.sup.3 represents
independently for each occurrence H; n is 2; and m is 1.
[0103] In certain embodiments, the present invention relates to a
compound represented by structure D, or a pharmaceutically
acceptable salt thereof:
##STR00004##
wherein
[0104] X represents --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.dbd.CH--, --CH.dbd.CHCH.sub.2--, --CH.sub.2CH.dbd.CH--,
--CH.dbd.CHCH.sub.2CH.sub.2--, --CH.sub.2CH.dbd.CHCH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CH--, or --CH.dbd.CHCH.dbd.CH--;
[0105] Y represents --CO.sub.2R'', --SO.sub.3H, --SO.sub.2NH.sub.2;
--B(OH).sub.2, --PO.sub.3H.sub.2, or 5-tetrazolyl;
[0106] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0107] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--;
[0108] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
and
[0109] n is 1, 2, 3, or 4.
[0110] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''.
[0111] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; and R'' represents
H.
[0112] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0113] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0114] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0115] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; or the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0116] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0117] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0118] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
[0119] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0120] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H.
[0121] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0122] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and n is 2.
[0123] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and the two instances of R' taken together represent
--(CH.sub.2).sub.4--.
[0124] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and n is 2.
[0125] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H or alkyl.
[0126] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; and n is 2.
[0127] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl; R' represents independently for each occurrence H,
alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or
heteroaralkyl; or the two instances of R' taken together represent
--(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--, --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, or --(CH.sub.2).sub.6--; and R'' represents H
or alkyl.
[0128] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and R'' represents H or alkyl.
[0129] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and R'' represents H or alkyl.
[0130] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H or alkyl; and n is 2.
[0131] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R'' represents H; and n is 2.
[0132] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H; and n is 2.
[0133] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H; and the two
instances of R' taken together represent --(CH.sub.2).sub.4--.
[0134] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H; the two instances
of R' taken together represent --(CH.sub.2).sub.4--; and n is
2.
[0135] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; and R'' represents H or
alkyl.
[0136] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; R'' represents H or alkyl; and
n is 2.
[0137] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H, or alkyl; R' represents
independently for each occurrence H, alkyl, alkenyl, alkynyl, aryl,
heteroaryl, aralkyl, or heteroaralkyl; or the two instances of R'
taken together represent --(CH.sub.2).sub.2--,
--(CH.sub.2).sub.3--, --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--,
or --(CH.sub.2).sub.6--; and R'' represents H or alkyl.
[0138] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H, or alkyl; the two instances of
R' taken together represent --(CH.sub.2).sub.4--; and R''
represents H or alkyl.
[0139] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; the two instances of R' taken
together represent --(CH.sub.2).sub.4--; and R'' represents H or
alkyl.
[0140] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; the two instances of R' taken
together represent --(CH.sub.2).sub.4--; R'' represents H or alkyl;
and n is 2.
[0141] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure D or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; the two instances of R' taken
together represent --(CH.sub.2).sub.4--; R'' represents H; and n is
2.
[0142] In certain embodiments, the present invention relates to a
compound represented by structure E, or a pharmaceutically
acceptable salt thereof:
##STR00005##
wherein
[0143] X represents --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.dbd.CH--, --CH.dbd.CHCH.sub.2--, --CH.sub.2CH.dbd.CH--,
--CH.dbd.CHCH.sub.2CH.sub.2--, --CH.sub.2CH.dbd.CHCH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CH--, or
--CH.dbd.CHCH.dbd.CH--;
[0144] Y represents --CO.sub.2R'', --SO.sub.3H, --SO.sub.2NH.sub.2;
--B(OH).sub.2, --PO.sub.3H.sub.2, or 5-tetrazolyl;
[0145] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0146] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl;
[0147] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
and
[0148] n is 1, 2, 3, or 4.
[0149] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''.
[0150] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; and R'' represents
H.
[0151] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0152] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0153] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0154] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl.
[0155] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl.
[0156] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0157] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H.
[0158] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0159] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and n is 2.
[0160] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H or alkyl.
[0161] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R'' represents H or alkyl; and n is 2.
[0162] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl; R' represents independently for each occurrence H,
alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or
heteroaralkyl; and R'' represents H or alkyl.
[0163] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H; and n is 2.
[0164] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; and R'' represents H or
alkyl.
[0165] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H; R'' represents H or alkyl; and
n is 2.
[0166] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure E or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R represents
independently for each occurrence H, or alkyl; R' represents
independently for each occurrence H, alkyl, alkenyl, alkynyl, aryl,
heteroaryl, aralkyl, or heteroaralkyl; and R'' represents H or
alkyl.
[0167] In certain embodiments, the present invention relates to a
compound represented by structure F, or a pharmaceutically
acceptable salt thereof:
##STR00006##
wherein
[0168] X represents --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.dbd.CH--, --CH.dbd.CHCH.sub.2--, --CH.sub.2CH.dbd.CH--,
--CH.dbd.CHCH.sub.2CH.sub.2--, --CH.sub.2CH.dbd.CHCH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CH--, or
--CH.dbd.CHCH.dbd.CH--;
[0169] Y represents --CO.sub.2R'', --SO.sub.3H, --SO.sub.2NH.sub.2;
--B(OH).sub.2, --PO.sub.3H.sub.2, or 5-tetrazolyl;
[0170] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl; and
[0171] R'' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
[0172] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''.
[0173] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; and R'' represents
H.
[0174] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0175] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0176] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0177] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H or alkyl.
[0178] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R'' represents H.
[0179] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H or alkyl.
[0180] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R'' represents H.
[0181] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H, alkyl, fluoride,
chloride, bromide, nitro, cyano, sulfonic acid, hydroxyl, alkoxyl,
thiol, alkylthio, formyl, acyl, formyloxy, acyloxy, formylthio,
acylthio, amino, alkylamino, formylamino, acylamino, or
carboxylate.
[0182] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H, or alkyl.
[0183] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; R'' represents H;
R represents independently for each occurrence H.
[0184] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure F or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein Y represents --CO.sub.2R''; and R'' represents
H or alkyl.
[0185] In certain embodiments, the present invention relates to a
compound represented by structure G, or a pharmaceutically
acceptable salt thereof:
##STR00007##
wherein
[0186] Y represents --SO.sub.3H, --SO.sub.2NH.sub.2; --B(OH).sub.2,
--PO.sub.3H.sub.2, or 5-tetrazolyl;
[0187] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0188] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--; and
[0189] n is 1, 2, 3, or 4.
[0190] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0191] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0192] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0193] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; or the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0194] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0195] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0196] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
[0197] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0198] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and n is 2.
[0199] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and the two instances of R' taken together represent
--(CH.sub.2).sub.4--.
[0200] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure G or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; and n is 2.
[0201] In certain embodiments, the present invention relates to a
compound represented by structure H, or a pharmaceutically
acceptable salt thereof:
##STR00008##
wherein
[0202] Y represents --SO.sub.3H, --SO.sub.2NH.sub.2; --B(OH).sub.2,
--PO.sub.3H.sub.2, or 5-tetrazolyl;
[0203] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0204] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
and
[0205] m is 1, 2, or 3.
[0206] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0207] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0208] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0209] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H or alkyl.
[0210] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H.
[0211] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein m is 1.
[0212] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R' represents independently for each occurrence H.
[0213] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure H or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R' represents independently for each occurrence H; and m is
1.
[0214] In certain embodiments, the present invention relates to a
compound represented by structure I, or a pharmaceutically
acceptable salt thereof:
##STR00009##
wherein
[0215] Y represents --SO.sub.3H, --SO.sub.2NH.sub.2; --B(OH).sub.2,
--PO.sub.3H.sub.2, or 5-tetrazolyl;
[0216] R represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
fluoride, chloride, bromide, iodide, nitro, cyano, sulfonic acid,
alkylsulfoxyl, arylsulfoxyl, heteroarylsulfoxyl, aralkylsulfoxyl,
heteroaralkylsulfoxyl, alkenylsulfoxyl, alkynylsulfoxyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, thiol, alkylthio, arylthio, aralkylthio,
heteroaralkylthio, alkenylthio, alkynylthio, formyl, acyl,
formyloxy, acyloxy, formylthio, acylthio, amino, alkylamino,
arylamino, heteroarylamino, aralkylamino, heteroaralkylamino,
alkenylamino, alkynylamino, formylamino, acylamino, carboxylate,
alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkyloxycarbonyl, heteroaralkyloxycarbonyl, carboxamido,
alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
aralkylaminocarbonyl, or heteroaralkylaminocarbonyl;
[0217] R' represents independently for each occurrence H, alkyl,
alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl,
alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl,
heteroaralkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, hydroxyl,
alkoxyl, aryloxyl, heteroaryloxyl, aralkyloxy, heteroaralkyloxy,
alkenyloxy, alkynyloxy, formyl, acyl, amino, alkylamino, arylamino,
heteroarylamino, aralkylamino, heteroaralkylamino, alkenylamino,
alkynylamino, formylamino, acylamino, alkyloxycarbonyl,
aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl,
heteroaralkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, aralkylaminocarbonyl, or
heteroaralkylaminocarbonyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--; --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6;
[0218] R.sup.3 represents independently for each occurrence H,
alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or
heteroaralkyl;
[0219] n is 1, 2, 3, or 4; and
[0220] m is 1, 2, or 3.
[0221] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, alkyl, fluoride, chloride, bromide, nitro, cyano, sulfonic acid,
hydroxyl, alkoxyl, thiol, alkylthio, formyl, acyl, formyloxy,
acyloxy, formylthio, acylthio, amino, alkylamino, formylamino,
acylamino, or carboxylate.
[0222] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H, or alkyl.
[0223] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H.
[0224] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
or heteroaralkyl; or the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0225] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R' represents independently for each
occurrence H, alkyl, or aralkyl; or the two instances of R' taken
together represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0226] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, or
--(CH.sub.2).sub.6--.
[0227] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein the two instances of R' taken together
represent --(CH.sub.2).sub.4--.
[0228] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R.sup.3 represents independently for each
occurrence H or alkyl.
[0229] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R.sup.3 represents independently for each
occurrence H.
[0230] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein n is 2.
[0231] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein m is 1.
[0232] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; and R.sup.3 represents independently for each occurrence H.
[0233] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; R.sup.3 represents independently for each occurrence H; and m is
1.
[0234] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R.sup.3 represents independently for each
occurrence H; and m is 1.
[0235] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R.sup.3 represents independently for each
occurrence H or alkyl; n is 2; and m is 1.
[0236] In certain embodiments, the present invention relates to any
of the aforementioned compounds represented by structure I or the
pharmaceutically acceptable salts thereof and the attendant
limitations, wherein R represents independently for each occurrence
H; the two instances of R' taken together represent
--(CH.sub.2).sub.4--; R.sup.3 represents independently for each
occurrence H; n is 2; and m is 1.
[0237] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable excipient.
[0238] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin;
and a pharmaceutically acceptable excipient.
[0239] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol; and a
pharmaceutically acceptable excipient.
[0240] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin; a
statin selected from the group consisting of atorvastatin,
cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin,
pravastatin, rosuvastatin, simvastatin, gemcabene, and probucol;
and a pharmaceutically acceptable excipient.
[0241] In certain embodiments, the present invention relates to any
of the aforementioned pharmaceutical compositions and the attendant
limitations, wherein said statin is lovastatin or atorvastatin.
[0242] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; a
glitazone selected from the group consisting of troglitazone,
rosiglitazone, and pioglitazone; and a pharmaceutically acceptable
excipient.
[0243] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin; a
glitazone selected from the group consisting of troglitazone,
rosiglitazone, and pioglitazone; and a pharmaceutically acceptable
excipient.
[0244] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; a fibrate
selected from the group consisting of fenofibrate and bezafibrate;
and a pharmaceutically acceptable excipient.
[0245] In certain embodiments, the present invention relates to a
pharmaceutical composition, comprising a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin; a
fibrate selected from the group consisting of fenofibrate and
bezafibrate; and a pharmaceutically acceptable excipient.
Methods of the Invention
[0246] A method of treating hyperlipidemia, hypercholesterolemia,
atherosclerosis, coronary artery disease, congestive heart failure,
cardiovascular disease, hypertension, coronary heart disease,
angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial
occlusive disease, obesity, hypothyroidism, vasoconstriction,
osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's
disease, lipodystrophy, or dyslipidemia, comprising the step
of:
[0247] administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention.
[0248] A method of treating hyperlipidemia, comprising the step
of:
[0249] administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention.
[0250] A method of raising serum high-density lipoprotein (HDL)
levels, comprising the step of:
[0251] administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention.
[0252] A method of lowering serum low-density lipoprotein (LDL)
levels, comprising the step of:
[0253] administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention.
[0254] A method of lowering serum lipoprotein (a) (Lp(a)) levels,
comprising the step of:
[0255] administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention.
[0256] A method of treating hyperlipidemia, hypercholesterolemia,
atherosclerosis, coronary artery disease, congestive heart failure,
cardiovascular disease, hypertension, coronary heart disease,
angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial
occlusive disease, obesity, hypothyroidism, vasoconstriction,
osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's
disease, lipodystrophy, or dyslipidemia, comprising the step
of:
[0257] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of niacin.
[0258] A method of treating hyperlipidemia, comprising the step of:
co-administering to a mammal in need thereof a therapeutically
effective amount of a compound of the present invention; and a
therapeutically effective amount of niacin.
[0259] A method of raising serum high-density lipoprotein (HDL)
levels in a mammal, comprising the step of:
[0260] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of niacin.
[0261] A method of lowering serum low-density lipoprotein (LDL)
levels in a mammal, comprising the step of:
[0262] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of niacin.
[0263] A method of lowering serum lipoprotein (a) (Lp(a)) levels in
a mammal, comprising the step of:
[0264] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of niacin.
[0265] A method of treating hyperlipidemia, hypercholesterolemia,
atherosclerosis, coronary artery disease, congestive heart failure,
cardiovascular disease, hypertension, coronary heart disease,
angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial
occlusive disease, obesity, hypothyroidism, vasoconstriction,
osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's
disease, lipodystrophy, or dyslipidemia, comprising the step
of:
[0266] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol.
[0267] A method of treating hyperlipidemia, comprising the step
of:
[0268] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol.
[0269] A method of raising serum high-density lipoprotein (HDL)
levels in a mammal, comprising the step of:
[0270] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol.
[0271] A method of lowering serum low-density lipoprotein (LDL)
levels in a mammal, comprising the step of:
[0272] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol.
[0273] A method of lowering serum lipoprotein (a) (Lp(a)) levels in
a mammal, comprising the step of:
[0274] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; and a therapeutically effective amount of a statin
selected from the group consisting of atorvastatin, cerivastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, gemcabene, and probucol.
[0275] A method of treating hyperlipidemia, hypercholesterolemia,
atherosclerosis, coronary artery disease, congestive heart failure,
cardiovascular disease, hypertension, coronary heart disease,
angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial
occlusive disease, obesity, hypothyroidism, vasoconstriction,
osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's
disease, lipodystrophy, or dyslipidemia, comprising the step
of:
[0276] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; a therapeutically effective amount of niacin; and a
therapeutically effective amount of a statin selected from the
group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol.
[0277] A method of treating hyperlipidemia, comprising the step
of:
[0278] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; a therapeutically effective amount of niacin; and a
therapeutically effective amount of a statin selected from the
group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol.
[0279] A method of raising serum high-density lipoprotein (HDL)
levels in a mammal, comprising the step of:
[0280] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; a therapeutically effective amount of niacin; and a
therapeutically effective amount of a statin selected from the
group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol.
[0281] A method of lowering serum low-density lipoprotein (LDL)
levels in a mammal, comprising the step of:
[0282] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; a therapeutically effective amount of niacin; and a
therapeutically effective amount of a statin selected from the
group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol.
[0283] A method of lowering serum lipoprotein (a) (Lp(a)) levels in
a mammal, comprising the step of:
[0284] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention; a therapeutically effective amount of niacin; and a
therapeutically effective amount of a statin selected from the
group consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin, gemcabene, and probucol.
[0285] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said statin is lovastatin or atorvastatin.
[0286] A method of treating diabetes in a mammal, comprising the
step of:
[0287] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention or a pharmaceutically acceptable salt thereof; and a
glitazone selected from the group consisting of troglitazone,
rosiglitazone, and pioglitazone.
[0288] A method of treating diabetes in a mammal, comprising the
step of:
[0289] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin;
and a glitazone selected from the group consisting of troglitazone,
rosiglitazone, and pioglitazone.
[0290] A method of treating diabetes in a mammal, comprising the
step of:
[0291] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention or a pharmaceutically acceptable salt thereof; and a
fibrate selected from the group consisting of fenofibrate and
bezafibrate.
[0292] A method of treating diabetes in a mammal, comprising the
step of:
[0293] co-administering to a mammal in need thereof a
therapeutically effective amount of a compound of the present
invention or a pharmaceutically acceptable salt thereof; niacin;
and a fibrate selected from the group consisting of fenofibrate and
bezafibrate.
[0294] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said mammal is a primate, bovine, ovine, rodent, equine,
canine, or feline.
[0295] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said mammal is a human.
[0296] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered by
inhalation.
[0297] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered orally.
[0298] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered
intravenously.
[0299] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered
sublingually.
[0300] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered ocularly.
[0301] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered
transdermally.
[0302] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered rectally.
[0303] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered vaginally.
[0304] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered topically.
[0305] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered
intramuscularly.
[0306] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered
subcutaneously.
[0307] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered buccally.
[0308] In certain embodiments, the present invention relates to any
of the aforementioned methods and the attendant limitations,
wherein said compound or compounds are administered nasally.
DEFINITIONS
[0309] For convenience, certain terms employed in the
specification, examples, and appended claims are collected
here.
[0310] The articles "a" and "an" are used herein to refer to one or
to more than one (i.e., to at least one) of the grammatical object
of the article. By way of example, "an element" means one element
or more than one element.
[0311] The terms "co-administration" and "co-administering" refer
to both concurrent administration (administration of two or more
therapeutic agents at the same time) and time varied administration
(administration of one or more therapeutic agents at a time
different from that of the administration of an additional
therapeutic agent or agents), as long as the therapeutic agents are
present in the patient to some extent at the same time.
[0312] The term "electron-withdrawing group" is recognized in the
art, and denotes the tendency of a substituent to attract valence
electrons from neighboring atoms, i.e., the substituent is
electronegative with respect to neighboring atoms. A quantification
of the level of electron-withdrawing capability is given by the
Hammett sigma (.sigma.) constant. This well known constant is
described in many references, for instance, J. March, Advanced
Organic Chemistry, McGraw Hill Book Company, New York, (1977
edition) pp. 251-259. The Hammett constant values are generally
negative for electron donating groups (.sigma.[P]=-0.66 for
NH.sub.2) and positive for electron withdrawing groups
(.sigma.[P]=0.78 for a nitro group), .sigma.[P] indicating para
substitution. Exemplary electron-withdrawing groups include nitro,
acyl, formyl, sulfonyl, trifluoromethyl, cyano, chloride, and the
like. Exemplary electron-donating groups include amino, methoxy,
and the like.
[0313] The term "aliphatic" is an art-recognized term and includes
linear, branched, and cyclic alkanes, alkenes, or alkynes. In
certain embodiments, aliphatic groups in the present invention are
linear or branched and have from 1 to about 20 carbon atoms.
[0314] The term "alkyl" is art-recognized, and includes saturated
aliphatic groups, including straight-chain alkyl groups,
branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl
substituted cycloalkyl groups, and cycloalkyl substituted alkyl
groups. In certain embodiments, a straight chain or branched chain
alkyl has about 30 or fewer carbon atoms in its backbone (e.g.,
C.sub.1-C.sub.30 for straight chain, C.sub.3-C.sub.30 for branched
chain), and alternatively, about 20 or fewer. Likewise, cycloalkyls
have from about 3 to about 10 carbon atoms in their ring structure,
and alternatively about 5, 6 or 7 carbons in the ring
structure.
[0315] Unless the number of carbons is otherwise specified, "lower
alkyl" refers to an alkyl group, as defined above, but having from
one to ten carbons, alternatively from one to about six carbon
atoms in its backbone structure. Likewise, "lower alkenyl" and
"lower alkynyl" have similar chain lengths.
[0316] The term "bicyclo-ring" as used herein refers to a bridged
ring system, such as a quinuclidine (shown below).
##STR00010##
[0317] The term "aralkyl" is art-recognized, and includes alkyl
groups substituted with an aryl group (e.g., an aromatic or
heteroaromatic group).
[0318] The terms "alkenyl" and "alkynyl" are art-recognized, and
include unsaturated aliphatic groups analogous in length and
possible substitution to the alkyls described above, but that
contain at least one double or triple bond respectively.
[0319] The term "heteroatom" is art-recognized, and includes an
atom of any element other than carbon or hydrogen. Illustrative
heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and
selenium, and alternatively oxygen, nitrogen or sulfur.
[0320] The term "aryl" is art-recognized, and includes 5-, 6- and
7-membered single-ring aromatic groups that may include from zero
to four heteroatoms, for example, benzene, naphthalene, anthracene,
pyrene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole,
triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine,
and the like. Those aryl groups having heteroatoms in the ring
structure may also be referred to as "heteroaryl" or
"heteroaromatics." The aromatic ring may be substituted at one or
more ring positions with such substituents as described above, for
example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl,
cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino,
amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether,
alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester,
heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl
(such as trifluoromethyl), cyano, or the like. The term "aryl" also
includes polycyclic ring systems having two or more cyclic rings in
which two or more carbons are common to two adjoining rings (the
rings are "fused rings") wherein at least one of the rings is
aromatic, e.g., the other cyclic rings may be cycloalkyls,
cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
[0321] The terms ortho (o-), meta (m-) and para (p-) are
art-recognized and apply to 1,2-, 1,3- and 1,4-disubstituted
benzenes, respectively. For example, the names 1,2-dimethylbenzene,
ortho-dimethylbenzene and o-dimethylbenzene are synonymous.
[0322] The terms "heterocyclyl" and "heterocyclic group" are
art-recognized, and include 3- to about 10-membered ring
structures, such as 3- to about 7-membered rings, whose ring
structures include one to four heteroatoms. Heterocycles may also
be polycycles. Heterocyclyl groups include, for example, thiophene,
thianthrene, furan, pyran, isobenzofuran, chromene, xanthene,
phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole,
pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole,
indole, indazole, purine, quinolizine, isoquinoline, quinoline,
phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline,
pteridine, carbazole, carboline, phenanthridine, acridine,
pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine,
furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole,
piperidine, piperazine, morpholine, lactones, lactams such as
azetidinones and pyrrolidinones, sultams, sultones, and the like.
The heterocyclic ring may be substituted at one or more positions
with such substituents as described above, as for example, halogen,
alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino,
nitro, sulfhydryl, imino, amido, phosphonate, phosphinate,
carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone,
aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic
moiety, fluoroalkyl (such as trifluoromethyl), cyano, or the
like.
[0323] The terms "polycyclyl" and "polycyclic group" are
art-recognized, and include structures with two or more rings
(e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or
heterocyclyls) in which two or more carbons are common to two
adjoining rings, e.g., the rings are "fused rings". Rings that are
joined through non-adjacent atoms, e.g., three or more atoms are
common to both rings, are termed "bridged" rings. Each of the rings
of the polycycle may be substituted with such substituents as
described above, as for example, halogen, alkyl, aralkyl, alkenyl,
alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino,
amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether,
alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an
aromatic or heteroaromatic moiety, fluoroalkyl (such as
trifluoromethyl), cyano, or the like.
[0324] The term "carbocycle" is art recognized and includes an
aromatic or non-aromatic ring in which each atom of the ring is
carbon. The flowing art-recognized terms have the following
meanings: "nitro" means --NO.sub.2; the term "halogen" designates
--F, --Cl, --Br or --I; the term "sulfhydryl" means --SH; the term
"hydroxyl" means --OH; and the term "sulfonyl" means
--SO.sub.2.sup.-.
[0325] The terms "amine" and "amino" are art-recognized and include
both unsubstituted and substituted amines, e.g., a moiety that may
be represented by the general formulas:
##STR00011##
wherein R50, R51 and R52 each independently represent a hydrogen,
an alkyl, an alkenyl, --(CH.sub.2).sub.m--R61, or R50 and R51,
taken together with the N atom to which they are attached complete
a heterocycle having from 4 to 8 atoms in the ring structure; R61
represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or
a polycycle; and m is zero or an integer in the range of 1 to 8. In
certain embodiments, only one of R50 or R51 may be a carbonyl,
e.g., R50, R51 and the nitrogen together do not form an imide. In
other embodiments, R50 and R51 (and optionally R52) each
independently represent a hydrogen, an alkyl, an alkenyl, or
--(CH.sub.2).sub.m--R61. Thus, the term "alkylamine" includes an
amine group, as defined above, having a substituted or
unsubstituted alkyl attached thereto, i.e., at least one of R50 and
R51 is an alkyl group.
[0326] The term "acylamino" is art-recognized and includes a moiety
that may be represented by the general formula:
##STR00012##
wherein R50 is as defined above, and R54 represents a hydrogen, an
alkyl, an alkenyl or --(CH.sub.2).sub.m--R61, where m and R61 are
as defined above.
[0327] The term "amido" is art recognized as an amino-substituted
carbonyl and includes a moiety that may be represented by the
general formula:
##STR00013##
wherein R50 and R51 are as defined above. Certain embodiments of
the amide in the present invention will not include amides which
may be unstable.
[0328] The term "alkylthio" is art recognized and includes an alkyl
group, as defined above, having a sulfur radical attached thereto.
In certain embodiments, the "alkylthio" moiety is represented by
one of --S-alkyl, --S-alkenyl, --S-alkynyl, and
--S--(CH.sub.2).sub.m--R61, wherein m and R61 are defined above.
Representative alkylthio groups include methylthio, ethylthio, and
the like.
[0329] The term "carbonyl" is art recognized and includes such
moieties as may be represented by the general formulas:
##STR00014##
wherein X50 is a bond or represents an oxygen or a sulfur, and R55
represents a hydrogen, an alkyl, an alkenyl,
--(CH.sub.2).sub.m--R61 or a pharmaceutically acceptable salt, R56
represents a hydrogen, an alkyl, an alkenyl or
--(CH.sub.2).sub.m--R61, where m and R61 are defined above. Where
X50 is an oxygen and R55 is not hydrogen, the formula represents an
"ester". Where X50 is an oxygen, and R55 is as first defined above,
the moiety is referred to herein as a carboxyl group, and
particularly when R55 is a hydrogen, the formula represents a
"carboxylic acid". Where X50 is an oxygen, and R56 is hydrogen, the
formula represents a "formate". In general, where the oxygen atom
of the above formula is replaced by sulfur, the formula represents
a "thiocarbonyl" group. Where X50 is a sulfur and R55 or R56 is not
hydrogen, the formula represents a "thioester." Where X50 is a
sulfur and R55 is hydrogen, the formula represents a
"thiocarboxylic acid." Where X50 is a sulfur and R56 is hydrogen,
the formula represents a "thioformate." On the other hand, where
X50 is a bond, and R55 is not hydrogen, the above formula
represents a "ketone" group. Where X50 is a bond, and R55 is
hydrogen, the above formula represents an "aldehyde" group.
[0330] The terms "oxime" and "oxime ether" are art-recognized and
refer to moieties that may be represented by the general
formula:
##STR00015##
wherein R75 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl,
aralkyl, or --(CH.sub.2).sub.m--R61. The moiety is an "oxime" when
R represents independently for each occurrence H; and it is an
"oxime ether" when R is alkyl, cycloalkyl, alkenyl, alkynyl, aryl,
aralkyl, or --(CH.sub.2).sub.m--R61.
[0331] The terms "alkoxyl" or "alkoxy" are art recognized and
include an alkyl group, as defined above, having an oxygen radical
attached thereto. Representative alkoxyl groups include methoxy,
ethoxy, propyloxy, tert-butoxy and the like. An "ether" is two
hydrocarbons covalently linked by an oxygen. Accordingly, the
substituent of an alkyl that renders that alkyl an ether is or
resembles an alkoxyl, such as may be represented by one of
--O-alkyl, --O-alkenyl, --O-alkynyl, --O--(CH.sub.2).sub.m--R61,
where m and R61 are described above.
[0332] The term "sulfonate" is art recognized and includes a moiety
that may be represented by the general formula:
##STR00016##
in which R57 is an electron pair, hydrogen, alkyl, cycloalkyl, or
aryl.
[0333] The term "sulfate" is art recognized and includes a moiety
that may be represented by the general formula:
##STR00017##
in which R57 is as defined above.
[0334] The term "sulfonamido" is art recognized and includes a
moiety that may be represented by the general formula:
##STR00018##
in which R50 and R56 are as defined above.
[0335] The term "sulfamoyl" is art-recognized and includes a moiety
that may be represented by the general formula:
##STR00019##
in which R50 and R51 are as defined above.
[0336] The term "sulfonyl" is art recognized and includes a moiety
that may be represented by the general formula:
##STR00020##
in which R58 is one of the following: hydrogen, alkyl, alkenyl,
alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0337] The term "sulfoxido" is art recognized and includes a moiety
that may be represented by the general formula:
##STR00021##
in which R58 is defined above.
[0338] The term "phosphoryl" is art-recognized and may in general
be represented by the formula:
##STR00022##
wherein Q50 represents S or O, and R59 represents hydrogen, a lower
alkyl or an aryl. When used to substitute, e.g., an alkyl, the
phosphoryl group of the phosphorylalkyl may be represented by the
general formulas:
##STR00023##
wherein Q50 and R59, each independently, are defined above, and Q51
represents O, S or N. When Q50 is S, the phosphoryl moiety is a
"phosphorothioate".
[0339] The term "phosphoramidite" is art recognized and includes
moieties represented by the general formulas:
##STR00024##
wherein Q51, R50, R51 and R59 are as defined above.
[0340] The term "phosphonamidite" is art recognized and includes
moieties represented by the general formulas:
##STR00025##
wherein Q51, R50, R51 and R59 are as defined above, and R60
represents a lower alkyl or an aryl.
[0341] The term "selenoalkyl" is art-recognized and refers to an
alkyl group having a substituted seleno group attached thereto.
Exemplary "selenoethers" which may be substituted on the alkyl are
selected from one of --Se-alkyl, --Se-alkenyl, --Se-alkynyl, and
--Se--(CH.sub.2).sub.m--R61, m and R61 being defined above.
[0342] The terms triflyl, tosyl, mesyl, and nonaflyl are
art-recognized and refer to trifluoromethanesulfonyl,
p-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl
groups, respectively. The terms triflate, tosylate, mesylate, and
nonaflate are art-recognized and refer to trifluoromethanesulfonate
ester, p-toluenesulfonate ester, methanesulfonate ester, and
nonafluorobutanesulfonate ester functional groups and molecules
that contain said groups, respectively.
[0343] The abbreviations Me, Et, Ph, Tf, Nf, Ts, and Ms represent
methyl, ethyl, phenyl, trifluoromethanesulfonyl,
nonafluorobutanesulfonyl, p-toluenesulfonyl and methanesulfonyl,
respectively. A more comprehensive list of the abbreviations
utilized by organic chemists of ordinary skill in the art appears
in the first issue of each volume of the Journal of Organic
Chemistry; this list is typically presented in a table entitled
Standard List of Abbreviations.
[0344] Certain compounds contained in compositions of the present
invention may exist in particular geometric or stereoisomeric
forms. In addition, polymers of the present invention may also be
optically active. The present invention contemplates all such
compounds, including cis- and trans-isomers, R- and S-enantiomers,
diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures
thereof, and other mixtures thereof, as falling within the scope of
the invention. Additional asymmetric carbon atoms may be present in
a substituent such as an alkyl group. All such isomers, as well as
mixtures thereof, are intended to be included in this
invention.
[0345] If, for instance, a particular enantiomer of compound of the
present invention is desired, it may be prepared by asymmetric
synthesis, or by derivation with a chiral auxiliary, where the
resulting diastereomeric mixture is separated and the auxiliary
group cleaved to provide the pure desired enantiomers.
Alternatively, where the molecule contains a basic functional
group, such as amino, or an acidic functional group, such as
carboxyl, diastereomeric salts are formed with an appropriate
optically-active acid or base, followed by resolution of the
diastereomers thus formed by fractional crystallization or
chromatographic means well known in the art, and subsequent
recovery of the pure enantiomers.
[0346] It will be understood that "substitution" or "substituted
with" includes the implicit proviso that such substitution is in
accordance with permitted valence of the substituted atom and the
substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation
such as by rearrangement, cyclization, elimination, or other
reaction.
[0347] The term "substituted" is also contemplated to include all
permissible substituents of organic compounds. In a broad aspect,
the permissible substituents include acyclic and cyclic, branched
and unbranched, carbocyclic and heterocyclic, aromatic and
nonaromatic substituents of organic compounds. Illustrative
substituents include, for example, those described herein above.
The permissible substituents may be one or more and the same or
different for appropriate organic compounds. For purposes of this
invention, the heteroatoms such as nitrogen may have hydrogen
substituents and/or any permissible substituents of organic
compounds described herein which satisfy the valences of the
heteroatoms. This invention is not intended to be limited in any
manner by the permissible substituents of organic compounds.
[0348] Analogous substitutions may be made to alkenyl and alkynyl
groups to produce, for example, aminoalkenyls, aminoalkynyls,
amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls,
thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or
alkynyls.
[0349] The definition of each expression, e.g. alkyl, m, n, etc.,
when it occurs more than once in any structure, is intended to be
independent of its definition elsewhere in the same structure
unless otherwise indicated expressly or by the context.
[0350] For purposes of the invention, the chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87,
inside cover.
Pharmaceutical Compositions
[0351] In another aspect, the present invention provides
pharmaceutically acceptable compositions which comprise a
therapeutically-effective amount of one or more of the compounds
described above, formulated together with one or more
pharmaceutically acceptable carriers (additives) and/or diluents.
As described in detail below, the pharmaceutical compositions of
the present invention may be specially formulated for
administration in solid or liquid form, including those adapted for
the following: (1) oral administration, for example, drenches
(aqueous or non-aqueous solutions or suspensions), tablets, e.g.,
those targeted for buccal, sublingual, and systemic absorption,
boluses, powders, granules, pastes for application to the tongue;
(2) parenteral administration, for example, by subcutaneous,
intramuscular, intravenous or epidural injection as, for example, a
sterile solution or suspension, or sustained-release formulation;
(3) topical application, for example, as a cream, ointment, or a
controlled-release patch or spray applied to the skin; (4)
intravaginally or intrarectally, for example, as a pessary, cream
or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8)
nasally; (9) pulmonary; or (10) intrathecally.
[0352] The phrase "therapeutically-effective amount" as used herein
means that amount of a compound, material, or composition
comprising a compound of the present invention which is effective
for producing some desired therapeutic effect in at least a
sub-population of cells in an animal at a reasonable benefit/risk
ratio applicable to any medical treatment.
[0353] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions, and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0354] The phrase "pharmaceutically-acceptable carrier" as used
herein means a pharmaceutically-acceptable material, composition or
vehicle, such as a liquid or solid filler, diluent, excipient,
manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc
stearate, or steric acid), or solvent encapsulating material,
involved in carrying or transporting the subject compound from one
organ, or portion of the body, to another organ, or portion of the
body. Each carrier must be "acceptable" in the sense of being
compatible with the other ingredients of the formulation and not
injurious to the patient. Some examples of materials which can
serve as pharmaceutically-acceptable carriers include: (1) sugars,
such as lactose, glucose and sucrose; (2) starches, such as corn
starch and potato starch; (3) cellulose, and its derivatives, such
as sodium carboxymethyl cellulose, ethyl cellulose and cellulose
acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc;
(8) excipients, such as cocoa butter and suppository waxes; (9)
oils, such as peanut oil, cottonseed oil, safflower oil, sesame
oil, olive oil, corn oil and soybean oil; (10) glycols, such as
propylene glycol; (11) polyols, such as glycerin, sorbitol,
mannitol and polyethylene glycol; (12) esters, such as ethyl oleate
and ethyl laurate; (13) agar; (14) buffering agents, such as
magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)
pyrogen-free water; (17) isotonic saline; (18) Ringer's solution;
(19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters,
polycarbonates and/or polyanhydrides; and (22) other non-toxic
compatible substances employed in pharmaceutical formulations.
[0355] As set out above, certain embodiments of the present
compounds may contain a basic functional group, such as amino or
alkylamino, and are, thus, capable of forming
pharmaceutically-acceptable salts with pharmaceutically-acceptable
acids. The term "pharmaceutically-acceptable salts" in this
respect, refers to the relatively non-toxic, inorganic and organic
acid addition salts of compounds of the present invention. These
salts can be prepared in situ in the administration vehicle or the
dosage form manufacturing process, or by separately reacting a
purified compound of the invention in its free base form with a
suitable organic or inorganic acid, and isolating the salt thus
formed during subsequent purification. Representative salts include
the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate,
nitrate, acetate, valerate, oleate, palmitate, stearate, laurate,
benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,
succinate, tartrate, napthylate, mesylate, glucoheptonate,
lactobionate, and laurylsulphonate salts and the like. (See, for
example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci.
66:1-19).
[0356] The pharmaceutically acceptable salts of the subject
compounds include the conventional nontoxic salts or quaternary
ammonium salts of the compounds, e.g., from non-toxic organic or
inorganic acids. For example, such conventional nontoxic salts
include those derived from inorganic acids such as hydrochloride,
hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like;
and the salts prepared from organic acids such as acetic,
propionic, succinic, glycolic, stearic, lactic, malic, tartaric,
citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic,
glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic,
fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic,
oxalic, isothionic, and the like.
[0357] In other cases, the compounds of the present invention may
contain one or more acidic functional groups and, thus, are capable
of forming pharmaceutically-acceptable salts with
pharmaceutically-acceptable bases. The term
"pharmaceutically-acceptable salts" in these instances refers to
the relatively non-toxic, inorganic and organic base addition salts
of compounds of the present invention. These salts can likewise be
prepared in situ in the administration vehicle or the dosage form
manufacturing process, or by separately reacting the purified
compound in its free acid form with a suitable base, such as the
hydroxide, carbonate or bicarbonate of a
pharmaceutically-acceptable metal cation, with ammonia, or with a
pharmaceutically-acceptable organic primary, secondary or tertiary
amine Representative alkali or alkaline earth salts include the
lithium, sodium, potassium, calcium, magnesium, and aluminum salts
and the like. Representative organic amines useful for the
formation of base addition salts include ethylamine, diethylamine,
ethylenediamine, ethanolamine, diethanolamine, piperazine and the
like. (See, for example, Berge et al., supra)
[0358] Wetting agents, emulsifiers and lubricants, such as sodium
lauryl sulfate and magnesium stearate, as well as coloring agents,
release agents, coating agents, sweetening, flavoring and perfuming
agents, preservatives and antioxidants can also be present in the
compositions.
[0359] Examples of pharmaceutically-acceptable antioxidants
include: (1) water soluble antioxidants, such as ascorbic acid,
cysteine hydrochloride, sodium bisulfate, sodium metabisulfite,
sodium sulfite and the like; (2) oil-soluble antioxidants, such as
ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol,
and the like; and (3) metal chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,
phosphoric acid, and the like.
[0360] Formulations of the present invention include those suitable
for oral, nasal, topical (including buccal and sublingual), rectal,
vaginal and/or parenteral administration. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any methods well known in the art of pharmacy. The amount of
active ingredient which can be combined with a carrier material to
produce a single dosage form will vary depending upon the host
being treated, the particular mode of administration. The amount of
active ingredient which can be combined with a carrier material to
produce a single dosage form will generally be that amount of the
compound which produces a therapeutic effect. Generally, out of one
hundred percent, this amount will range from about 0.1 percent to
about ninety-nine percent of active ingredient, preferably from
about 5 percent to about 70 percent, most preferably from about 10
percent to about 30 percent.
[0361] In certain embodiments, a formulation of the present
invention comprises an excipient selected from the group consisting
of cyclodextrins, celluloses, liposomes, micelle forming agents,
e.g., bile acids, and polymeric carriers, e.g., polyesters and
polyanhydrides; and a compound of the present invention. In certain
embodiments, an aforementioned formulation renders orally
bioavailable a compound of the present invention.
[0362] Methods of preparing these formulations or compositions
include the step of bringing into association a compound of the
present invention with the carrier and, optionally, one or more
accessory ingredients. In general, the formulations are prepared by
uniformly and intimately bringing into association a compound of
the present invention with liquid carriers, or finely divided solid
carriers, or both, and then, if necessary, shaping the product.
[0363] Formulations of the invention suitable for oral
administration may be in the form of capsules, cachets, pills,
tablets, lozenges (using a flavored basis, usually sucrose and
acacia or tragacanth), powders, granules, or as a solution or a
suspension in an aqueous or non-aqueous liquid, or as an
oil-in-water or water-in-oil liquid emulsion, or as an elixir or
syrup, or as pastilles (using an inert base, such as gelatin and
glycerin, or sucrose and acacia) and/or as mouth washes and the
like, each containing a predetermined amount of a compound of the
present invention as an active ingredient. A compound of the
present invention may also be administered as a bolus, electuary or
paste.
[0364] In solid dosage forms of the invention for oral
administration (capsules, tablets, pills, dragees, powders,
granules, trouches and the like), the active ingredient is mixed
with one or more pharmaceutically-acceptable carriers, such as
sodium citrate or dicalcium phosphate, and/or any of the following:
(1) fillers or extenders, such as starches, lactose, sucrose,
glucose, mannitol, and/or silicic acid; (2) binders, such as,
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone,
sucrose and/or acacia; (3) humectants, such as glycerol; (4)
disintegrating agents, such as agar-agar, calcium carbonate, potato
or tapioca starch, alginic acid, certain silicates, and sodium
carbonate; (5) solution retarding agents, such as paraffin; (6)
absorption accelerators, such as quaternary ammonium compounds and
surfactants, such as poloxamer and sodium lauryl sulfate; (7)
wetting agents, such as, cetyl alcohol, glycerol monostearate, and
non-ionic surfactants; (8) absorbents, such as kaolin and bentonite
clay; (9) lubricants, such as talc, calcium stearate, magnesium
stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc
stearate, sodium stearate, stearic acid, and mixtures thereof; (10)
coloring agents; and (11) controlled-release agents, such as
crospovidone or ethyl cellulose. In the case of capsules, tablets
and pills, the pharmaceutical compositions may also comprise
buffering agents. Solid compositions of a similar type may also be
employed as fillers in soft and hard-shelled gelatin capsules using
such excipients as lactose or milk sugars, as well as high
molecular weight polyethylene glycols and the like.
[0365] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared using binder (for example, gelatin or hydroxypropylmethyl
cellulose), lubricant, inert diluent, preservative, disintegrant
(for example, sodium starch glycolate or cross-linked sodium
carboxymethyl cellulose), surface-active or dispersing agent.
Molded tablets may be made by molding in a suitable machine a
mixture of the powdered compound moistened with an inert liquid
diluent.
[0366] The tablets, and other solid dosage forms of the
pharmaceutical compositions of the present invention, such as
dragees, capsules, pills and granules, may optionally be scored or
prepared with coatings and shells, such as enteric coatings and
other coatings well known in the pharmaceutical-formulating art.
They may also be formulated so as to provide slow or controlled
release of the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the
desired release profile, other polymer matrices, liposomes and/or
microspheres. They may be formulated for rapid release, e.g.,
freeze-dried. They may be sterilized by, for example, filtration
through a bacteria-retaining filter, or by incorporating
sterilizing agents in the form of sterile solid compositions which
can be dissolved in sterile water, or some other sterile injectable
medium immediately before use. These compositions may also
optionally contain opacifying agents and may be of a composition
that they release the active ingredient(s) only, or preferentially,
in a certain portion of the gastrointestinal tract, optionally, in
a delayed manner. Examples of embedding compositions which can be
used include polymeric substances and waxes. The active ingredient
can also be in micro-encapsulated form, if appropriate, with one or
more of the above-described excipients.
[0367] Liquid dosage forms for oral administration of the compounds
of the invention include pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active ingredient, the liquid dosage forms may
contain inert diluents commonly used in the art, such as, for
example, water or other solvents, solubilizing agents and
emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, oils (in particular,
cottonseed, groundnut, corn, germ, olive, castor and sesame oils),
glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty
acid esters of sorbitan, and mixtures thereof.
[0368] Besides inert diluents, the oral compositions can also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring, coloring, perfuming and
preservative agents.
[0369] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar and tragacanth, and mixtures thereof.
[0370] Formulations of the pharmaceutical compositions of the
invention for rectal or vaginal administration may be presented as
a suppository, which may be prepared by mixing one or more
compounds of the invention with one or more suitable non-irritating
excipients or carriers comprising, for example, cocoa butter,
polyethylene glycol, a suppository wax or a salicylate, and which
is solid at room temperature, but liquid at body temperature and,
therefore, will melt in the rectum or vaginal cavity and release
the active compound.
[0371] Formulations of the present invention which are suitable for
vaginal administration also include pessaries, tampons, creams,
gels, pastes, foams or spray formulations containing such carriers
as are known in the art to be appropriate.
[0372] Dosage forms for the topical or transdermal administration
of a compound of this invention include powders, sprays, ointments,
pastes, creams, lotions, gels, solutions, patches and inhalants.
The active compound may be mixed under sterile conditions with a
pharmaceutically-acceptable carrier, and with any preservatives,
buffers, or propellants which may be required.
[0373] The ointments, pastes, creams and gels may contain, in
addition to an active compound of this invention, excipients, such
as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones,
bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
[0374] Powders and sprays can contain, in addition to a compound of
this invention, excipients such as lactose, talc, silicic acid,
aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain
customary propellants, such as chlorofluorohydrocarbons and
volatile unsubstituted hydrocarbons, such as butane and
propane.
[0375] Transdermal patches have the added advantage of providing
controlled delivery of a compound of the present invention to the
body. Such dosage forms can be made by dissolving or dispersing the
compound in the proper medium. Absorption enhancers can also be
used to increase the flux of the compound across the skin. The rate
of such flux can be controlled by either providing a rate
controlling membrane or dispersing the compound in a polymer matrix
or gel.
[0376] Ophthalmic formulations, eye ointments, powders, solutions
and the like, are also contemplated as being within the scope of
this invention.
[0377] Pharmaceutical compositions of this invention suitable for
parenteral administration comprise one or more compounds of the
invention in combination with one or more
pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous
solutions, dispersions, suspensions or emulsions, or sterile
powders which may be reconstituted into sterile injectable
solutions or dispersions prior to use, which may contain sugars,
alcohols, antioxidants, buffers, bacteriostats, solutes which
render the formulation isotonic with the blood of the intended
recipient or suspending or thickening agents.
[0378] Examples of suitable aqueous and nonaqueous carriers that
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained,
for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0379] These compositions may also contain adjuvants, such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms upon the subject
compounds may be ensured by the inclusion of various antibacterial
and antifungal agents, for example, paraben, chlorobutanol, phenol
sorbic acid, and the like. It may also be desirable to include
isotonic agents, such as sugars, sodium chloride, and the like into
the compositions. In addition, prolonged absorption of the
injectable pharmaceutical form may be brought about by the
inclusion of agents which delay absorption, such as aluminum
monostearate and gelatin.
[0380] In some cases, in order to prolong the effect of a drug, it
is desirable to slow the absorption of the drug from subcutaneous
or intramuscular injection. This result may be accomplished by the
use of a liquid suspension of crystalline or amorphous material
having poor water solubility. The rate of absorption of the drug
then depends upon its rate of dissolution which, in turn, may
depend upon crystal size and crystalline form. Alternatively,
delayed absorption of a parenterally-administered drug form is
accomplished by dissolving or suspending the drug in an oil
vehicle.
[0381] Injectable depot forms are made by forming microencapsule
matrices of the subject compounds in biodegradable polymers, such
as polylactide-polyglycolide. Depending on the ratio of drug to
polymer, and the nature of the particular polymer employed, the
rate of drug release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions which are
compatible with body tissue.
[0382] When the compounds of the present invention are administered
as pharmaceuticals, to humans and animals, they can be given per se
or as a pharmaceutical composition containing, for example, 0.1 to
99% (more preferably, 10 to 30%) of active ingredient in
combination with a pharmaceutically acceptable carrier.
[0383] The preparations of the present invention may be given
orally, parenterally, topically, or rectally. They are of course
given in forms suitable for each administration route. For example,
they are administered in tablets or capsule form, by injection,
inhalation, eye lotion, ointment, suppository, administration by
injection, infusion or inhalation; topical by lotion or ointment;
and rectal by suppositories. Oral administrations are
preferred.
[0384] The phrases "parenteral administration" and "administered
parenterally" as used herein mean modes of administration other
than enteral and topical administration, usually by injection, and
include, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticulare, subcapsular,
subarachnoid, intraspinal and intrasternal injection and
infusion.
[0385] The phrases "systemic administration," "administered
systemically," "peripheral administration" and "administered
peripherally" as used herein mean the administration of a compound,
drug or other material other than directly into the central nervous
system, such that it enters the patient's system and, thus, is
subject to metabolism and other like processes, for example,
subcutaneous administration.
[0386] Compounds may be administered to humans and other animals
for therapy by any suitable route of administration, including
orally, nasally, as by, for example, a spray, rectally,
intravaginally, parenterally, intracisternally and topically, as by
powders, ointments or drops, including buccally and
sublingually.
[0387] Regardless of the route of administration selected, the
compounds of the present invention, which may be used in a suitable
hydrated form, and/or the pharmaceutical compositions of the
present invention, are formulated into pharmaceutically-acceptable
dosage forms by conventional methods known to those of skill in the
art.
[0388] Actual dosage levels of the active ingredients in the
pharmaceutical compositions of this invention may be varied so as
to obtain an amount of the active ingredient which is effective to
achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, without being toxic to the
patient.
[0389] The selected dosage level will depend upon a variety of
factors including the activity of the particular compound of the
present invention employed, or the ester, salt or amide thereof,
the route of administration, the time of administration, the rate
of excretion or metabolism of the particular compound being
employed, the rate and extent of absorption, the duration of the
treatment, other drugs, compounds and/or materials used in
combination with the particular compound employed, the age, sex,
weight, condition, general health and prior medical history of the
patient being treated, and like factors well known in the medical
arts.
[0390] A physician or veterinarian having ordinary skill in the art
can readily determine and prescribe the effective amount of the
pharmaceutical composition required. For example, the physician or
veterinarian could start doses of the compounds of the invention
employed in the pharmaceutical composition at levels lower than
that required in order to achieve the desired therapeutic effect
and gradually increase the dosage until the desired effect is
achieved.
[0391] In general, a suitable daily dose of a compound of the
invention will be that amount of the compound which is the lowest
dose effective to produce a therapeutic effect. Such an effective
dose will generally depend upon the factors described above.
Generally, oral, intravenous, intracerebroventricular and
subcutaneous doses of the compounds of this invention for a
patient, when used for the indicated analgesic effects, will range
from about 0.0001 to about 100 mg per kilogram of body weight per
day.
[0392] If desired, the effective daily dose of the active compound
may be administered as two, three, four, five, six or more
sub-doses administered separately at appropriate intervals
throughout the day, optionally, in unit dosage forms. Preferred
dosing is one administration per day.
[0393] While it is possible for a compound of the present invention
to be administered alone, it is preferable to administer the
compound as a pharmaceutical formulation (composition).
[0394] The compounds according to the invention may be formulated
for administration in any convenient way for use in human or
veterinary medicine, by analogy with other pharmaceuticals.
[0395] In another aspect, the present invention provides
pharmaceutically acceptable compositions which comprise a
therapeutically-effective amount of one or more of the subject
compounds, as described above, formulated together with one or more
pharmaceutically acceptable carriers (additives) and/or diluents.
As described in detail below, the pharmaceutical compositions of
the present invention may be specially formulated for
administration in solid or liquid form, including those adapted for
the following: (1) oral administration, for example, drenches
(aqueous or non-aqueous solutions or suspensions), tablets,
boluses, powders, granules, pastes for application to the tongue;
(2) parenteral administration, for example, by subcutaneous,
intramuscular or intravenous injection as, for example, a sterile
solution or suspension; (3) topical application, for example, as a
cream, ointment or spray applied to the skin, lungs, or mucous
membranes; or (4) intravaginally or intrarectally, for example, as
a pessary, cream or foam; (5) sublingually or buccally; (6)
ocularly; (7) transdermally; or (8) nasally.
[0396] The term "treatment" is intended to encompass also
prophylaxis, therapy and cure.
[0397] The patient receiving this treatment is any animal in need,
including primates, in particular humans, and other mammals, such
as equines, cattle, swine and sheep; and poultry and pets in
general.
[0398] The compound of the invention can be administered as such or
in admixtures with pharmaceutically acceptable carriers and can
also be administered in conjunction with antimicrobial agents such
as penicillins, cephalosporins, aminoglycosides and glycopeptides.
Conjunctive therapy, thus includes sequential, simultaneous and
separate administration of the active compound in a way that the
therapeutical effects of the first administered one is not entirely
disappeared when the subsequent is administered.
Micelles
[0399] Microemulsification technology improves bioavailability of
some lipophilic (water insoluble) pharmaceutical agents. Examples
include Trimetrine (Dordunoo, S. K., et al., Drug Development and
Industrial Pharmacy, 17(12), 1685-1713, 1991 and REV 5901 (Sheen,
P. C., et al., J Pharm Sci 80(7), 712-714, 1991). Among other
things, microemulsification provides enhanced bioavailability by
preferentially directing absorption to the lymphatic system instead
of the circulatory system, which thereby bypasses the liver, and
prevents destruction of the compounds in the hepatobiliary
circulation.
[0400] While all suitable amphiphilic carriers are contemplated,
the presently preferred carriers are generally those that have
Generally-Recognized-as-Safe (GRAS) status, and that can both
solubilize the compound of the present invention and microemulsify
it at a later stage when the solution comes into a contact with a
complex water phase (such as one found in human gastro-intestinal
tract). Usually, amphiphilic ingredients that satisfy these
requirements have HLB (hydrophilic to lipophilic balance) values of
2-20, and their structures contain straight chain aliphatic
radicals in the range of C-6 to C-20. Examples are
polyethylene-glycolized fatty glycerides and polyethylene
glycols.
[0401] Commercially available amphiphilic carriers are particularly
contemplated, including Gelucire-series, Labrafil, Labrasol, or
Lauroglycol (all manufactured and distributed by Gattefosse
Corporation, Saint Priest, France), PEG-mono-oleate, PEG-di-oleate,
PEG-mono-laurate and di-laurate, Lecithin, Polysorbate 80, etc
(produced and distributed by a number of companies in USA and
worldwide).
Polymers
[0402] Hydrophilic polymers suitable for use in the present
invention are those which are readily water-soluble, can be
covalently attached to a vesicle-forming lipid, and which are
tolerated in vivo without toxic effects (i.e., are biocompatible).
Suitable polymers include polyethylene glycol (PEG), polylactic
(also termed polylactide), polyglycolic acid (also termed
polyglycolide), a polylactic-polyglycolic acid copolymer, and
polyvinyl alcohol. Preferred polymers are those having a molecular
weight of from about 100 or 120 Daltons up to about 5,000 or 10,000
Daltons, and more preferably from about 300 Daltons to about 5,000
Daltons. In a particularly preferred embodiment, the polymer is
polyethyleneglycol having a molecular weight of from about 100 to
about 5,000 Daltons, and more preferably having a molecular weight
of from about 300 to about 5,000 Daltons. In a particularly
preferred embodiment, the polymer is polyethyleneglycol of 750
Daltons (PEG(750)). Polymers may also be defined by the number of
monomers therein; a preferred embodiment of the present invention
utilizes polymers of at least about three monomers, such PEG
polymers consisting of three monomers (approximately 150
Daltons).
[0403] Other hydrophilic polymers which may be suitable for use in
the present invention include polyvinylpyrrolidone,
polymethoxazoline, polyethyloxazoline, polyhydroxypropyl
methacrylamide, polymethacrylamide, polydimethylacrylamide, and
derivatized celluloses such as hydroxymethylcellulose or
hydroxyethylcellulose.
[0404] In certain embodiments, a formulation of the present
invention comprises a biocompatible polymer selected from the group
consisting of polyamides, polycarbonates, polyalkylenes, polymers
of acrylic and methacrylic esters, polyvinyl polymers,
polyglycolides, polysiloxanes, polyurethanes and co-polymers
thereof, celluloses, polypropylene, polyethylenes, polystyrene,
polymers of lactic acid and glycolic acid, polyanhydrides,
poly(ortho)esters, poly(butic acid), poly(valeric acid),
poly(lactide-co-caprolactone), polysaccharides, proteins,
polyhyaluronic acids, polycyanoacrylates, and blends, mixtures, or
copolymers thereof.
Cyclodextrins
[0405] Cyclodextrins are cyclic oligosaccharides, consisting of 6,
7 or 8 glucose units, designated by the Greek letters alpha, beta
and gamma, respectively. The glucose units are linked by
alpha-1,4-glucosidic bonds. As a consequence of the chair
conformation of the sugar units, all secondary hydroxyl groups (at
C-2, C-3) are located on one side of the ring, while all the
primary hydroxyl groups at C-6 are situated on the other side. As a
result, the external faces are hydrophilic, making the
cyclodextrins water-soluble. In contrast, the cavities of the
cyclodextrins are hydrophobic, since they are lined by the hydrogen
of atoms C-3 and C-5, and by ether-like oxygens. These matrices
allow complexation with a variety of relatively hydrophobic
compounds, including, for instance, steroid compounds such as
17-beta-estradiol (see, e.g., van Uden et al. Plant Cell Tiss. Org.
Cult. 38:1-3-113 (1994)). The complexation takes place by Van der
Waals interactions and by hydrogen bond formation. For a general
review of the chemistry of cyclodextrins, see, Wenz, Agnew. Chem.
Int. Ed. Engl., 33:803-822 (1994).
[0406] The physico-chemical properties of the cyclodextrin
derivatives depend strongly on the kind and the degree of
substitution. For example, their solubility in water ranges from
insoluble (e.g., triacetyl-beta-cyclodextrin) to 147% soluble (w/v)
(G-2-beta-cyclodextrin). In addition, they are soluble in many
organic solvents. The properties of the cyclodextrins enable the
control over solubility of various formulation components by
increasing or decreasing their solubility.
[0407] Numerous cyclodextrins and methods for their preparation
have been described. For example, Parmeter (I), et al. (U.S. Pat.
No. 3,453,259; incorporated by reference) and Gramera, et al. (U.S.
Pat. No. 3,459,731; incorporated by reference) described
electroneutral cyclodextrins. Other derivatives include
cyclodextrins with cationic properties [Parmeter (II), U.S. Pat.
No. 3,453,257; incorporated by reference], insoluble crosslinked
cyclodextrins (Solms, U.S. Pat. No. 3,420,788; incorporated by
reference), and cyclodextrins with anionic properties [Parmeter
(III), U.S. Pat. No. 3,426,011; incorporated by reference]. Among
the cyclodextrin derivatives with anionic properties, carboxylic
acids, phosphorous acids, phosphinous acids, phosphonic acids,
phosphoric acids, thiophosphonic acids, thiosulphinic acids, and
sulfonic acids have been appended to the parent cyclodextrin [see,
Parmeter (III), supra]. Furthermore, sulfoalkyl ether cyclodextrin
derivatives have been described by Stella, et al. (U.S. Pat. No.
5,134,127; incorporated by reference).
Liposomes
[0408] Liposomes consist of at least one lipid bilayer membrane
enclosing an aqueous internal compartment. Liposomes may be
characterized by membrane type and by size. Small unilamellar
vesicles (SUVs) have a single membrane and typically range between
0.02 and 0.05 .mu.m in diameter; large unilamellar vesicles (LUVS)
are typically larger than 0.05 .mu.m Oligolamellar large vesicles
and multilamellar vesicles have multiple, usually concentric,
membrane layers and are typically larger than 0.1 .mu.m. Liposomes
with several nonconcentric membranes, i.e., several smaller
vesicles contained within a larger vesicle, are termed
multivesicular vesicles.
[0409] One aspect of the present invention relates to formulations
comprising liposomes containing a compound of the present
invention, where the liposome membrane is formulated to provide a
liposome with increased carrying capacity. Alternatively or in
addition, the compound of the present invention may be contained
within, or adsorbed onto, the liposome bilayer of the liposome. The
compound of the present invention may be aggregated with a lipid
surfactant and carried within the liposome's internal space; in
these cases, the liposome membrane is formulated to resist the
disruptive effects of the active agent-surfactant aggregate.
[0410] According to one embodiment of the present invention, the
lipid bilayer of a liposome contains lipids derivatized with
polyethylene glycol (PEG), such that the PEG chains extend from the
inner surface of the lipid bilayer into the interior space
encapsulated by the liposome, and extend from the exterior of the
lipid bilayer into the surrounding environment.
[0411] Active agents contained within liposomes of the present
invention are in solubilized form. Aggregates of surfactant and
active agent (such as emulsions or micelles containing the active
agent of interest) may be entrapped within the interior space of
liposomes according to the present invention. A surfactant acts to
disperse and solubilize the active agent, and may be selected from
any suitable aliphatic, cycloaliphatic or aromatic surfactant,
including but not limited to biocompatible lysophosphatidylcholines
(LPCs) of varying chain lengths (for example, from about C14 to
about C20). Polymer-derivatized lipids such as PEG-lipids may also
be utilized for micelle formation as they will act to inhibit
micelle/membrane fusion, and as the addition of a polymer to
surfactant molecules decreases the CMC of the surfactant and aids
in micelle formation. Preferred are surfactants with CMCs in the
micromolar range; higher CMC surfactants may be utilized to prepare
micelles entrapped within liposomes of the present invention,
however, micelle surfactant monomers could affect liposome bilayer
stability and would be a factor in designing a liposome of a
desired stability.
[0412] Liposomes useful in the present invention may be prepared by
any of a variety of techniques that are known in the art. See,
e.g., U.S. Pat. No. 4,235,871; Published PCT applications WO
96/14057; New RRC, Liposomes: A practical approach, IRL Press,
Oxford (1990), pages 33-104; Lasic DD, Liposomes from physics to
applications, Elsevier Science Publishers BV, Amsterdam, 1993.
[0413] For example, liposomes useful in the present invention may
be prepared by diffusing a lipid derivatized with a hydrophilic
polymer into preformed liposomes, such as by exposing preformed
liposomes to micelles composed of lipid-grafted polymers, at lipid
concentrations corresponding to the final mole percent of
derivatized lipid which is desired in the liposome. Liposomes
containing a hydrophilic polymer can also be formed by
homogenization, lipid-field hydration, or extrusion techniques, as
are known in the art.
[0414] In one aspect of the present invention, the liposomes have
substantially homogeneous sizes in a selected size range. One
effective sizing method involves extruding an aqueous suspension of
the liposomes through a series of polycarbonate membranes having a
selected uniform pore size; the pore size of the membrane will
correspond roughly with the largest sizes of liposomes produced by
extrusion through that membrane. See e.g., U.S. Pat. No. 4,737,323
(Apr. 12, 1988).
Release Modifiers
[0415] The release characteristics of a formulation of the present
invention depend on the encapsulating material, the concentration
of encapsulated drug, and the presence of release modifiers. For
example, release can be manipulated to be pH dependent using a pH
sensitive coating that releases only at a low pH, as in the
stomach, or a higher pH, as in the intestine. An enteric coating
can be used to prevent release from occurring until after passage
through the stomach. Multiple coatings or mixtures of cyanamide
encapsulated in different materials can be used to obtain an
initial release in the stomach, followed by later release in the
intestine. Release can also be manipulated by inclusion of salts or
pore forming agents, which can increase water uptake or release of
drug by diffusion from the capsule. Excipients which modify the
solubility of the drug can also be used to control the release
rate. Agents which enhance degradation of the matrix or release
from the matrix can also be incorporated. They can be added to the
drug, added as a separate phase (i.e., as particulates), or can be
co-dissolved in the polymer phase depending on the compound. In all
cases the amount should be between 0.1 and thirty percent (w/w
polymer). Types of degradation enhancers include inorganic salts,
such as ammonium sulfate and ammonium chloride, organic acids, such
as citric acid, benzoic acid, and ascorbic acid, inorganic bases,
such as sodium carbonate, potassium carbonate, calcium carbonate,
zinc carbonate, and zinc hydroxide, and organic bases, such as
protamine sulfate, spermine, choline, ethanolamine, diethanolamine,
and triethanolamine and surfactants, such as Tween.RTM. and
Pluronic.RTM.. Pore forming agents which add microstructure to the
matrices (i.e., water soluble compounds, such as inorganic salts
and sugars) are added as particulates. The range should be between
one and thirty percent (w/w polymer).
[0416] Uptake can also be manipulated by altering residence time of
the particles in the gut. This can be achieved, for example, by
coating the particle with, or selecting as the encapsulating
material, a mucosal adhesive polymer. Examples include most
polymers with free carboxyl groups, such as chitosan, celluloses,
and especially polyacrylates (as used herein, polyacrylates refers
to polymers including acrylate groups and modified acrylate groups
such as cyanoacrylates and methacrylates).
EXEMPLIFICATION
[0417] The invention now being generally described, it will be more
readily understood by reference to the following examples, which
are included merely for purposes of illustration of certain aspects
and embodiments of the present invention, and are not intended to
limit the invention.
Example 1
Synthesis of 4-pyridin-3-yl-but-3-enoic acid (Compound 2035)
[0418] ##STR00026## [0419] Reaction conditions: (a) Ethyl acrylate,
Ph.sub.3P, n-hexanol, 140.degree. C., 4 hr, 55%; (b): NaOH,
MeOH--H.sub.2O, 98%.
[0420] The target compound 4-pyridin-3-yl-but-3-enoic acid
(Compound 2035) was prepared by two steps starting from the
commercial available 3-Pyridinecarboxaldehyde. Reaction of this
aldehyde with ethyl acrylate and triphenylphosphine in a sealed
tube for 4 hr at 140.degree. C. gave ethyl
4-pyridin-3-yl-3-butenoate in a 55% yield. Kirby, Anthony J.;
Walwyn, David R. Effective molarities for intramolecular hydride
transfer. Reduction by 1,4-dihydropyridines of the neighboring
.alpha.-ketoester group. Gazzetta Chimica Italiana (1987), 117(11),
667-80. This reaction is a self-priming Wittig reaction and the
yield was not optimized. Gilbert Stork, R. A. Kretchmer, R. H.
Schlessinger. The Stereospecific Total Synthesis of dl-Lycopodine.
J. Am. Chem. Soc. (1968), 90, 1647. Hydrolysis of the ester using
the routine condition and the subsequent purification with
preparative HPLC afforded the target compound 2035 with almost
quantitative yield.
Example 2
Synthesis of 4-[6-(2-pyrrolidin-1-yl-ethyl)-pyridin-3-yl]-but-3
enoic acid (Compound 2035B)
[0421] ##STR00027## [0422] Reaction conditions: (a) LiAlH.sub.4,
THF, 0.degree. C., 4 hr, 80%; b) MnO.sub.2, CH.sub.2Cl.sub.2, r.
t., 18 hr, 60%; c) Ethyl acrylate, Ph.sub.3P, n-hexanol,
140.degree. C., 4 hr; d) NaOH, MeOH--H.sub.2O, 4% yield for the two
steps.
[0423] The target compound
4-[6-(2-pyrrolidin-1-yl-ethyl)-pyridin-3-yl]-but-3-enoic acid
(Compound 2035B) was prepared by four steps starting from the
commercial available 6-[2-(Pyrrolidin-1-yl)ethyl]pyridine 1.
Firstly, reduction of acid 1 with lithium aluminum hydride was
performed in THF at 0.degree. C. for 4 hr, providing alcohol 2 in a
yield of 80%. Compound 2 was then oxidized to the corresponding
aldehyde 3 using Manganese (IV) oxides as the reagent in a yield of
60%. Delarue, S.; Girault, S.; Maes, L.; Debreu-Fontaine, M.-A.;
Labaeid, M.; Grellier, P.; Sergheraert, C. Synthesis and in Vitro
and in Vivo Antimalarial Activity of New 4-Anilinoquinolines. J.
Med. Chem. 2001, 44(17), 2827-2833. Reaction of this aldehyde with
ethyl acrylate and triphenylphosphine in a sealed tube for 4 hr at
140.degree. C. gave ethyl
4-[6-(2-pyrrolidin-1-yl-ethyl)-pyridin-3-yl]-but-3-enoic acid,
which on subsequent hydrolysis using the routine condition followed
by purification with preparative HPLC afforded the target compound
2035B as a TFA salt with a 4% yield. Kirby, Anthony J.; Walwyn,
David R. Effective molarities for intramolecular hydride transfer.
Reduction by 1,4-dihydropyridines of the neighboring
.alpha.-ketoester group. Gazzetta Chimica Italiana (1987), 117(11),
667-80. However, the yields were not optimized.
Example 3
Synthesis of Compound 2035C
[0424] Reagents: i) ethyl pyruvate; ii) (-)-8-phenylmenthol; iii)
L-Selectride; iv) base.
##STR00028##
[0425] LC/MS data for 2035C--The peak at 7.3 min showed: 180
[M+H].
[0426] Gradient: 0-5 min: 0% ACN; 5-15 min: 0-5% ACN; 15-25 min:
5-98% ACN.
Example 4
Synthesis of Compound 2035D
Reagents: i) Ph.sub.3PCH.sub.2CH.sub.2CO.sub.2H.
##STR00029##
[0428] LC/MS data for 2035D--the peak at 17.4 min showed: 178
[M+H].
[0429] Gradient: 0-5 min: 2% ACN; 5-20 min: 2-15% ACN; 20-30 min:
15-98% ACN.
Example 5
Synthesis of Compound 2805
[0430] Reagents: i) Methaneboronic acid, 16%; ii) Ethyl acrylate;
iii) NaOH, 35% yield for the last two steps.
##STR00030##
[0431] LC/MS data of 2805--Calculated MW is 177; observed (the peak
at 11.2 min, TIC): 178 [M+H].
[0432] Gradient: 0-5 min: 5% ACN; 5-20 min: 5-10% ACN; 20-30 min:
10-98%.
Example 6
Synthesis of Compound 2805B
[0433] Reagents: i) 1-Ethaneboronic acid, 43%; ii) Ethyl acrylate;
iii) NaOH, 30% yield for the last two steps.
##STR00031##
[0434] LC/MS data of 2805B--confirmed preparation of target
compound.
[0435] Gradient: 0-5 min: 5% ACN; 5-20 min: 5-15% ACN; 20-30 min:
15-98% ACN.
Example 7
Synthesis of Compound 2805C
[0436] Reagents: i) 1-Propaneboronic acid, 31%; ii) Ethyl acrylate;
iii) NaOH, total yield of the two steps was .about.24%.
##STR00032##
[0437] LC/MS data of 2805C--Calculated MW is 205; observed (the
peak at 13.4 min, TIC): 206 [M+H]. Gradient: 0-5 min: 10% ACN; 5-20
min: 10-30% ACN.
Example 8
Synthesis of Compound 2805D
[0438] Reagents: i) 1-Butaneboronic acid, 55%; ii) Ethyl acrylate;
iii) NaOH, total yield of the two steps was .about.60%.
##STR00033##
[0439] LC/MS data of 2805D--Calculated MW is 219; observed (the
peak of 20.9 min): 220 [M+H].
[0440] Gradient: 0-5 min: 2% ACN; 5-20 min: 2-30% ACN; 20-35 min:
30-98% ACN.
Example 9
Outline of Hep G 2 Cell Assay Experimental Protocol
[0441] Split HepG2 cells in 24 well plates 2.about.3 days prior to
niacin treatment, 0.5 mL complete DMEM media is added per well
[0442] Cells were pre-incubated with niacin (1 mM) for 24.about.48
h
[0443] Wash HepG2 cells 3 times with PBS
[0444] Incubate HepG2 cells in 250 mL medium C(DMEM containing 5
mg/mL fatty acid free BSA), containing .sup.125I-labelled HDL (5-10
mg/mL with specificity ofo 300-500 cpm/ng HDL protein. For 16 h
[0445] Aspirate the media and wash the cells with 0.5 mL of 0.1
mg/mL BSA-PBS twice, and with PBS twice
[0446] Cells were digested in 250 mL of 1 N NaOH at room
temperature overnight
[0447] 100 mL of cell lysate was used for gamma-counting
[0448] 100 mL of cell lysate was used for protein assay by BCA
method
[0449] HDL uptake activity is expressed as "cpm of .sup.125I-HDL
uptake/mg of cell protein.
Example 10
Outline of PGD2 Assay Experimental Protocol
[0450] THP-1 cells were grown in RPMI complete media
[0451] 2.times.10.sup.6 cells/well in 24 well flask were seeded in
serum free media containing 16 nM/mL of PMA. Cells were allowed to
differentiate into macrophages for 12 hours
[0452] The media was replaced with complete RPMI media and
incubation continued for 5 hours
[0453] After incubation, media was aspirated and cells were treated
with niacin and niacin analogs in 1 mL of serum free RPMI
media.
[0454] Incubated for 30 min. 100 mL of media was collected, PGD2
secreted was derivitized into stable MOX derivative.
[0455] PGD2 in the sample was assayed by using PGD2 assay kit from
Cayman chemicals.
INCORPORATION BY REFERENCE
[0456] All of the U.S. patents and U.S. patent application
publications cited herein are hereby incorporated by reference.
EQUIVALENTS
[0457] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
* * * * *